Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001091355 | SCV001247338 | uncertain significance | not provided | 2019-12-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003353156 | SCV004065669 | uncertain significance | Inborn genetic diseases | 2023-08-02 | criteria provided, single submitter | clinical testing | The c.359G>A (p.S120N) alteration is located in exon 2 (coding exon 1) of the MYO9A gene. This alteration results from a G to A substitution at nucleotide position 359, causing the serine (S) at amino acid position 120 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |